ATE555384T1 - Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika - Google Patents

Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika

Info

Publication number
ATE555384T1
ATE555384T1 AT08011630T AT08011630T ATE555384T1 AT E555384 T1 ATE555384 T1 AT E555384T1 AT 08011630 T AT08011630 T AT 08011630T AT 08011630 T AT08011630 T AT 08011630T AT E555384 T1 ATE555384 T1 AT E555384T1
Authority
AT
Austria
Prior art keywords
testing
response
cells
action
therapeutic drugs
Prior art date
Application number
AT08011630T
Other languages
English (en)
Inventor
Barbara Mayer
Original Assignee
Spherotec Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spherotec Gmbh filed Critical Spherotec Gmbh
Application granted granted Critical
Publication of ATE555384T1 publication Critical patent/ATE555384T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT08011630T 2008-06-26 2008-06-26 Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika ATE555384T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08011630A EP2138844B1 (de) 2008-06-26 2008-06-26 Verfahren zum Testen der Reaktion von Zellen auf die Einwirkung von Therapeutika

Publications (1)

Publication Number Publication Date
ATE555384T1 true ATE555384T1 (de) 2012-05-15

Family

ID=40152534

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08011630T ATE555384T1 (de) 2008-06-26 2008-06-26 Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika

Country Status (4)

Country Link
US (2) US20090325178A1 (de)
EP (1) EP2138844B1 (de)
AT (1) ATE555384T1 (de)
CA (1) CA2670484A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2642276A1 (de) * 2012-03-22 2013-09-25 Inoviem Scientific Verfahren zur dynamischen Spektroskopie unter physiologischen Zuständen
RU2653442C2 (ru) * 2015-12-29 2018-05-08 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) Способ персонифицированного скрининга действия препаратов на лейкозные клетки ex vivo
CN106859800B (zh) * 2017-02-27 2018-03-06 滨州医学院 一种肿瘤种植器
CN112316993B (zh) * 2020-10-30 2022-04-08 临沂大学 一种单细胞阵列的获取方法
CA3200578A1 (en) * 2020-11-24 2022-06-02 Duke University Droplet organoid-based immuno-oncology assays and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023172A (en) * 1986-07-14 1991-06-11 The Research Foundation Of State University Of New York Predictive assay for tumor control
US5155034A (en) 1988-06-30 1992-10-13 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Three-dimensional cell to tissue assembly process
US5153131A (en) 1990-12-11 1992-10-06 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration High aspect reactor vessel and method of use
US4988623A (en) 1988-06-30 1991-01-29 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Rotating bio-reactor cell culture apparatus
US5026650A (en) 1988-06-30 1991-06-25 The United States Of Amercia As Represented By The Administrator Of The National Aeronautics And Space Administration Horizontally rotated cell culture system with a coaxial tubular oxygenator
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
CA2336624C (en) 1998-07-06 2008-10-21 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties
EP2015783A4 (de) 2006-05-08 2010-07-21 Hitachi Chemical Co Ltd Verfahren zur überprüfung der wirkstoffempfindlichkeit fester tumore durch quantifizierung der mrna-expression in dünn geschnittenem tumorgewebe

Also Published As

Publication number Publication date
US20090325178A1 (en) 2009-12-31
US20150377863A1 (en) 2015-12-31
EP2138844B1 (de) 2012-04-25
EP2138844A1 (de) 2009-12-30
CA2670484A1 (en) 2009-12-26

Similar Documents

Publication Publication Date Title
WO2011156734A3 (en) Method of characterizing vascular diseases
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
WO2013158309A3 (en) Non-disruptive gene targeting
MX2009002936A (es) Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf.
AR088514A1 (es) Inmunoligantes biespecificos dirigidos contra tnf
DE602007005629D1 (de) Reversibles siRNA-Silencing eines mutierten und endogenen Huntington-Wildtypgens und dessen Anwendung zur Behandlung von Morbus Huntington
BR112013020724A2 (pt) vestimenta para uso por um ser vivo, em que a vestimenta é adaptada para uso para fornecer um mapa da atividade elétrica, sistema, método e programa de computador para fornercer um mapa de atividade elétrica do coração de um ser vivo por meio de sinais elétricos do coração obtidos por uma série de eletrodos da superfície que são dispostos sobre uma superfície externa do ser vivo
EP2831284A4 (de) Zusammensetzungen und verfahren zur sammlung und isolierung von nucleinsäuren aus biologischen proben
BRPI1006215A2 (pt) " anticorpos multiespecíficos, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibição de uma atividade bíologica e uso do anticorpo "
AR084373A1 (es) Composiciones y metodos para la eliminacion de biopeliculas
WO2010105275A3 (en) Method to assess human allograft status from microrna expression levels
BR112013008703A2 (pt) "método e sistema de indicador biológico de esterilização"
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
AR085397A1 (es) Combinacion de inhibidores de quinasa y sus usos
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
EA201390147A1 (ru) Система циркуляции
EP2209495A4 (de) Taz/wwtr1 zur diagnose und behandlung von krebs
EP2460880A4 (de) Marker und reagens für den nachweis von humanen il-17-produzierenden helfer-t-zellen sowie verfahren für den nachweis von humanen il-17-produzierenden helfer-t-zellen
ATE555384T1 (de) Verfahren zum testen der reaktion von zellen auf die einwirkung von therapeutika
BR112013009713A2 (pt) método para identificação de alta produtividade antagonistas microbianos contra patógenos
BRPI0921026A2 (pt) avaliação do sistema circulatório de um indivíduo
CU20120126A7 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
ATE511645T1 (de) Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme
DE602005006990D1 (de) Wiederherstellung zerstörten gewebes mit hilfe von multipotenten zellen